The results of this study showed that most of the recruited patients were obese, had MetS, and had poor glycemic control despite using almost the maximum basal insulin dose of 0.43 (±0.26) unit/kg/day recommended by the ADA 2024 guideline. Here, INS is linked to metabolic syndrome.